Increased EBV DNAemia after Anti-SARS-CoV-2 Vaccination in Solid Organ Transplants
Vaccines
; 10(7), 2022.
Article
in English
| EuropePMC | ID: covidwho-1970718
ABSTRACT
The reactivation of latent viruses during SARS-CoV-2 infection is well recognized, and coinfection with Epstein–Barr virus (EBV) has been associated with severe clinical cases of COVID-19 infection. In transplant patients, EBV infection presents a significant challenge. Assessing the potential impact of SARS-CoV-2 vaccinations on EBV infections in stable kidney and liver transplant recipients was the objective of our study. Ten solid-organ-transplant (SOT) patients (eight kidney and two liver) vaccinated with standard doses of mRNA COVID-19 vaccines were included. EBV DNA viral load measurements were conducted prior to the vaccination and during a follow-up period (at the first month and after six months) after the second vaccine dose. After the second dose, a significant increase in median viremia was observed (p < 0.01) in 9 patients, and in one patient, the reactivation of EBV infection was found. Six months later, the median viremia decreased significantly (p < 0.05). The EBV viral load should be closely monitored as it could lead to the earlier diagnosis and treatment of EBV-related complications. Despite experiencing a decrease in the viral load six months post-vaccination, some patients still had a viral load over the baseline, which increased the risk of potential complications.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Topics:
Vaccines
Language:
English
Journal:
Vaccines
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS